# Personalised cancer vaccines at commodity cost through fully automated manufacturing

Source: https://onco.cc/ideas/idea-moon-neoantigen-vaccines-at-scale/  
OnCo record `idea-moon-neoantigen-vaccines-at-scale` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vaccines tailored to each patient's tumour mutations are showing real benefit but cost a fortune to make. Automate the whole process so a personalised vaccine costs about as much as a course of chemotherapy.

## Summary

Individualised neoantigen mRNA vaccines have shown reduced recurrence in melanoma with pembrolizumab (phase 2b, with phase 3 ongoing) and immune responses in pancreatic cancer, but require bespoke sequencing, epitope selection and GMP manufacture per patient at very high cost. The proposal is an engineering programme for end-to-end automation: standardised sample-to-sequence pipelines, validated epitope prediction, continuous-flow mRNA synthesis and formulation in closed robotic units sited regionally, and regulatory acceptance of platform-based release testing, targeting a manufactured cost under a few thousand dollars and turnaround under three weeks.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Automated regional manufacturing reduces per-patient vaccine cost by over 90% and turnaround to under three weeks without loss of immunogenicity, making adjuvant personalised vaccination affordable for common cancers if phase 3 trials confirm efficacy.
- Rationale: The science of neoantigen vaccination is maturing; if it works, access will be decided by manufacturing cost. The COVID-19 mRNA scale-up showed the platform can be industrialised.
- Proposed test: Build one automated regional unit and demonstrate cost, turnaround and product equivalence against conventional manufacture in an ongoing adjuvant vaccine trial.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Prices and value): Prasad, De Jesús & Mailankody, The high price of anticancer drugs: origins, implications, barriers, solutions (Nat Rev Clin Oncol 2017): https://doi.org/10.1038/nrclinonc.2017.31

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- drugs: [Autogene cevumeran](https://onco.cc/drugs/autogene-cevumeran/), [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Moderna](https://onco.cc/companies/moderna/)
- terms: [Neoantigen](https://onco.cc/terms/neoantigen/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [No one can predict who responds to immunotherapy](https://onco.cc/bottlenecks/b-immunotherapy-response/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [The high price of anticancer drugs: origins, implications, barriers, solutions](https://onco.cc/key-papers/paper-prasad-nat-rev-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-moon-neoantigen-vaccines-at-scale.json